Later, the results of a meta-analysis on PTX concluded that it exerted a significant reduction effect on the levels of TNF-α and CRP in disorders such as CAD where the reduction in TNF-α was correlated with the treatment duration but not the PTX dose. This evidence concerns the gene CRP and coronary artery disorder.